1. Home
  2. RRX vs DVA Comparison

RRX vs DVA Comparison

Compare RRX & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regal Rexnord Corporation

RRX

Regal Rexnord Corporation

HOLD

Current Price

$159.98

Market Cap

9.0B

Sector

N/A

ML Signal

HOLD

Logo DaVita Inc.

DVA

DaVita Inc.

HOLD

Current Price

$104.88

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RRX
DVA
Founded
1955
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
8.2B
IPO Year
1987
1995

Fundamental Metrics

Financial Performance
Metric
RRX
DVA
Price
$159.98
$104.88
Analyst Decision
Buy
Hold
Analyst Count
10
4
Target Price
$169.80
$145.00
AVG Volume (30 Days)
645.5K
801.2K
Earning Date
02-04-2026
02-12-2026
Dividend Yield
0.89%
N/A
EPS Growth
22.48
5.63
EPS
3.87
9.76
Revenue
$5,872,300,000.00
$13,317,965,000.00
Revenue This Year
N/A
$6.50
Revenue Next Year
$3.67
$2.97
P/E Ratio
$40.87
$10.84
Revenue Growth
N/A
5.14
52 Week Low
$90.56
$101.00
52 Week High
$167.78
$179.60

Technical Indicators

Market Signals
Indicator
RRX
DVA
Relative Strength Index (RSI) 65.11 29.58
Support Level $148.51 $101.00
Resistance Level $157.84 $106.38
Average True Range (ATR) 5.05 3.05
MACD 1.04 -0.77
Stochastic Oscillator 95.91 26.82

Price Performance

Historical Comparison
RRX
DVA

About RRX Regal Rexnord Corporation

Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The four operating segments include Commercial Systems, Industrial Systems, Climate Solutions, and Motion Control Solutions.

About DVA DaVita Inc.

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.

Share on Social Networks: